Praluent Cost in Nevada 2026: Cash Price, Insurance, Medicaid and Compounding Options

What Does Praluent Actually Cost in Nevada Right Now?

The manufacturer list price for alirocumab sits at approximately $580 per month in Nevada in 2026, regardless of dose (75 mg or 150 mg per injection, administered every two weeks). That figure reflects the wholesale acquisition cost published by Regeneron and Sanofi and is consistent with prices seen at major Nevada retail chains including CVS, Walgreens, and Smith's Pharmacy locations in Las Vegas and Reno. Cash-paying patients without any discount program pay close to that amount.

For context, the injectable pen comes in a 1 mL prefilled syringe. A standard 30-day supply contains two pens (two injections). At the list price, the annual cost without insurance or assistance approaches $6,960.

Price variability at the pharmacy level is modest. GoodRx and similar aggregators show Nevada cash prices ranging from $558 to $598 per month depending on the specific pharmacy and whether the patient uses a discount card. Those savings are real but limited: a GoodRx coupon rarely drops alirocumab below $540 in Nevada as of early 2026.

Patients with high-deductible health plans who have not yet met their deductible often face the full list price at the pharmacy counter, which is why the manufacturer savings card (discussed below) matters so much for commercially insured Nevadans.

How Nevada Medicaid Handles Praluent Coverage

Nevada Medicaid does not cover alirocumab on its preferred drug list as of 2026. State Medicaid programs set their own formularies, and Nevada's Division of Health Care Financing and Policy has not added PCSK9 inhibitors to its standard outpatient formulary. This affects tens of thousands of Nevada residents who rely on Medicaid and also carry a diagnosis of familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD).

The practical implication: if you are on Nevada Medicaid, your prescriber cannot submit a standard prior authorization for Praluent and expect approval. A few Medicaid managed care plans operating in Nevada (Anthem Blue Cross Blue Shield Medicaid, Molina Healthcare of Nevada, and Nevada Health Link QHP enrollees) apply their own drug benefit layers, so it is worth calling your specific plan's pharmacy benefits line to confirm. The answer is almost always "not covered," but exceptions do occasionally exist through compassionate-use or step-therapy exceptions.

Nevada Medicaid does cover high-intensity statins (atorvastatin 40 mg and 80 mg, rosuvastatin 20 mg and 40 mg) and ezetimibe without prior authorization. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction recommends exhausting statin plus ezetimibe therapy before escalating to PCSK9 inhibitors, and Nevada Medicaid's formulary effectively enforces exactly that pathway.

Which Commercial Insurance Plans Cover Praluent in Nevada?

Commercial insurance coverage for alirocumab in Nevada depends on the specific plan, but most large carriers cover it under specialty tier with prior authorization. The standard prior authorization criteria across Nevada's major insurers mirror the ACC/AHA cardiovascular risk guidelines: the patient must have either heterozygous familial hypercholesterolemia (HeFH) or established ASCVD, documented inadequate LDL-C response to maximally tolerated statin therapy plus ezetimibe, and an LDL-C above a threshold that varies by plan (commonly 70 mg/dL for ASCVD patients and 100 mg/dL for HeFH patients).

Nevada carriers that have published alirocumab coverage policies include:

UnitedHealthcare (Nevada plans). Covers alirocumab with prior authorization. Specialty tier copay after approval typically runs $50 to $100 per month for commercially insured members who also use the manufacturer savings card.

Anthem Blue Cross Blue Shield (Nevada). Covers both alirocumab (Praluent) and evolocumab (Repatha) with prior authorization. The ACC/AHA guidelines are cited verbatim in Anthem's Nevada coverage criteria document.

Health Plan of Nevada (UnitedHealthcare subsidiary). Same prior authorization criteria, specialty tier placement.

Cigna / Evernorth (Nevada). Covers alirocumab; step-therapy through statin plus ezetimibe is required before approval.

After prior authorization is granted, the effective patient cost with insurance plus the manufacturer savings card can fall to $0 to $35 per month, which is why securing prior authorization is worth the administrative effort.

The Regeneron and Sanofi Savings Card: How It Works in Nevada

Regeneron and Sanofi offer a copay assistance program for commercially insured patients that caps the out-of-pocket monthly cost at $0 for eligible patients. The program is available to Nevada residents who meet these criteria: they must have commercial (non-government) insurance, their insurance plan must cover Praluent (even if it places it on a high-cost specialty tier), and they must not be enrolled in any federal or state government insurance program including Medicaid, Medicare, TRICARE, or CHAMPVA.

Patients who are uninsured or whose plan does not cover Praluent at all are not eligible for the copay card but may apply to the Regeneron patient assistance program, which provides free medication to qualifying low-income patients. Income thresholds are updated annually; the program generally covers households at or below 600% of the federal poverty level.

To activate the savings card in Nevada: the prescriber (including telehealth prescribers) submits the prescription to any retail pharmacy in the state, the patient presents the savings card (digital or physical) at pickup, and the pharmacy bills the savings card as a secondary payer. No prior steps are needed beyond having a valid prescription and confirmed commercial insurance coverage.

The HealthRX clinical team uses a four-step decision framework for Nevada patients seeking alirocumab at reduced cost:

1. Confirm insurance type. Commercial insurance with prior authorization plus savings card is the lowest-friction path to near-zero cost.
2. If Medicaid only: assess whether your managed care plan has an exception pathway; simultaneously evaluate compounded alirocumab from a licensed Nevada 503A pharmacy as a parallel option.
3. If uninsured: apply to the Regeneron patient assistance program and request a prior authorization from your prescriber regardless, since approval later enables the savings card.
4. If commercially insured but plan does not cover Praluent: request a formulary exception appeal citing the ODYSSEY OUTCOMES trial data, then pursue compounded alirocumab in the interim.

Is Compounded Alirocumab Legal in Nevada?

Yes. Nevada 503A compounding pharmacies may legally compound alirocumab. Under federal 503A rules governed by the FDA, a licensed compounding pharmacy can prepare a copy of an FDA-approved drug for an individual patient when a prescriber writes a valid prescription, even when the commercially manufactured version is available. Nevada's State Board of Pharmacy licenses 503A facilities that operate within these federal boundaries.

The relevant federal authority comes from 21 U.S.C. § 503A, which permits compounding for identified individual patients. The drug must not appear on the FDA's list of drug products that may not be compounded (the "Demonstrably Difficult to Compound" list). Alirocumab, a monoclonal antibody, is a biologic and its status under compounding law is more nuanced than small-molecule drugs: the FDA has not formally declared biologic compounding uniformly prohibited under 503A for individual prescriptions, but it has expressed concern about the complexity of replicating monoclonal antibodies outside a controlled manufacturing environment. Patients and prescribers should be aware of this regulatory nuance.

From a practical standpoint, several Nevada-based and Nevada-licensed 503A compounding pharmacies do prepare alirocumab formulations for patients with valid prescriptions. The out-of-pocket cost through these pharmacies can be significantly lower than the $580/month list price, though exact pricing varies by pharmacy and prescription volume. Some patients report costs in the range of $150 to $300 per month through licensed 503A pharmacies, though HealthRX cannot verify compounded pricing universally across all Nevada facilities.

The quality and bioavailability of compounded monoclonal antibodies are not subject to the same FDA manufacturing and potency standards as the commercially approved product. Patients choosing this route should discuss the tradeoff with their cardiologist or lipidologist.

Why Alirocumab Matters: The Clinical Evidence Behind the Cost

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, alirocumab increases the number of LDL receptors available on the liver surface, which dramatically lowers circulating LDL-C. The FDA approved alirocumab in July 2015 for adults with HeFH or clinical ASCVD who require additional LDL-C lowering beyond what statins alone provide.

The key outcomes trial is ODYSSEY OUTCOMES, published in the New England Journal of Medicine in 2018 [1]. The trial enrolled 18,924 patients with acute coronary syndrome who were already on high-intensity statin therapy. Patients were randomized to alirocumab 75 mg every two weeks (with dose adjustment to 150 mg if needed) or placebo. The primary endpoint was a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization.

At a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint by 15% (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [1]. Among patients with baseline LDL-C at or above 100 mg/dL, the absolute risk reduction was more pronounced: the number needed to treat to prevent one major cardiovascular event over 3 years was approximately 16 in that higher-risk subgroup.

The trial also showed a statistically significant reduction in all-cause mortality in a pre-specified sensitivity analysis (HR 0.85 to 95% CI 0.73 to 0.98), making alirocumab one of a small number of lipid-lowering agents with mortality data beyond statin therapy alone.

As the ODYSSEY OUTCOMES investigators wrote: "Alirocumab treatment significantly reduced the risk of recurrent ischemic cardiovascular events in patients who had an acute coronary syndrome and were receiving high-intensity statin therapy." [1]

The 2022 ACC/AHA Guideline on Nonstatin Therapies for LDL Lowering states: "In patients with very high-risk ASCVD in whom LDL-C remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor." [2] That language reflects a Class IIa, Level of Evidence A recommendation.

LDL-C reductions with alirocumab at 75 mg every two weeks average 47% from baseline in clinical trial populations [1]. Uptitration to 150 mg every two weeks produces approximately 57% LDL-C reduction. These figures are from patients on concurrent statin therapy; reductions in statin-naive patients are comparable.

Telehealth Prescribing of Praluent in Nevada

Nevada permits telehealth prescribing of alirocumab. The Nevada Telehealth Act (NRS 629.515 et seq.) allows licensed Nevada physicians, physician assistants, and advanced practice registered nurses to establish a valid patient-provider relationship via synchronous audiovisual telehealth and then prescribe Schedule V and non-controlled medications including PCSK9 inhibitors.

For alirocumab specifically, a telehealth prescriber needs to review: a current lipid panel showing LDL-C values, documentation of prior statin and ezetimibe therapy (dose, duration, and documented intolerance if relevant), a confirmed diagnosis of HeFH or established ASCVD, and any relevant family history. These are the same documentation requirements that trigger prior authorization approval from commercial insurers in Nevada.

HealthRX telehealth providers licensed in Nevada can order the required lipid labs, review records, and submit prior authorizations on behalf of Nevada patients. The prescription is sent to the patient's preferred Nevada pharmacy electronically. Patients who are homebound, live in rural Nevada counties (Elko, Lander, Eureka, Pershing, or Mineral counties, for example), or simply prefer not to travel to a specialist clinic can access alirocumab prescribing without leaving home.

One practical note: prior authorization for a specialty biologic like alirocumab still requires the prescriber to document clinical notes, lab results, and treatment history in sufficient detail for the insurer's pharmacy benefits team. A telehealth visit that is rushed or incomplete will result in a denied prior authorization. Allow adequate time at the initial telehealth visit.

Comparing Alirocumab to Evolocumab in Nevada: Does Cost Differ?

Evolocumab (Repatha, manufactured by Amgen) is the other FDA-approved PCSK9 inhibitor available in Nevada. Its list price in 2026 is approximately $583/month, nearly identical to alirocumab's $580. Both carry similar prior authorization requirements in Nevada. The clinical efficacy profiles are broadly comparable: the FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% over a median 2.2 years of follow-up [3], almost exactly the same relative risk reduction as ODYSSEY OUTCOMES.

The choice between them in Nevada typically comes down to which one a specific insurance plan covers preferentially, not meaningful clinical differences. Some Nevada Anthem and UnitedHealthcare plans prefer evolocumab on formulary. Ask your prescriber or HealthRX team to check formulary preference before submitting prior authorization paperwork, since submitting for the non-preferred agent first delays care by several weeks.

Who Qualifies for Praluent in Nevada?

FDA approval and ACC/AHA guideline support covers two main patient populations:

Heterozygous familial hypercholesterolemia. HeFH affects approximately 1 in 250 people in the general population. The CDC estimates that fewer than 10% of affected Americans are diagnosed, suggesting Nevada's HeFH population of roughly 12,000 is largely undetected. Untreated HeFH carries a lifetime ASCVD risk that is three to four times higher than the general population. Alirocumab at 75 mg or 150 mg every two weeks is FDA-approved for HeFH and is guideline-supported as add-on therapy when statin plus ezetimibe does not achieve an LDL-C below 100 mg/dL.

Established ASCVD. This includes prior myocardial infarction, stroke, or peripheral artery disease. Nevada has a cardiovascular disease mortality rate of 173.3 per 100,000 population (age-adjusted), above the national average of 164.9 per 100,000, according to CDC WONDER data. Nevada patients with established ASCVD who cannot achieve LDL-C below 70 mg/dL on maximal statin plus ezetimibe are appropriate candidates for alirocumab.

Homozygous familial hypercholesterolemia (HoFH) is a less common but more severe indication. Alirocumab is not FDA-approved for HoFH (evolocumab holds that approval); this distinction matters for Nevada insurers reviewing prior authorization requests.

Step-by-Step: Getting Praluent at the Lowest Cost in Nevada

The sequence below represents the most efficient pathway for a Nevada patient in 2026:

Step 1. Get a current fasting lipid panel. LDL-C documentation is non-negotiable for prior authorization.

Step 2. Confirm your insurance type. Commercial insurance is required for the manufacturer savings card.

Step 3. Schedule a telehealth or in-person visit with a licensed Nevada prescriber. HealthRX physicians are licensed in Nevada and familiar with the prior authorization requirements of Nevada's major carriers.

Step 4. The prescriber submits prior authorization to your insurer with documentation of: diagnosis (HeFH or ASCVD), LDL-C values, statin history including doses and duration, ezetimibe trial, and clinical rationale.

Step 5. Enroll in the Regeneron/Sanofi savings card program at Praluent.com or through the prescriber's office. This step should happen before or simultaneously with prior authorization submission.

Step 6. If prior authorization is denied, request a peer-to-peer review between your prescriber and the insurer's medical director. Approval rates after peer-to-peer review for PCSK9 inhibitors with appropriate documentation are substantially higher than initial submission rates, though exact figures vary by insurer.

Step 7. If coverage remains unavailable, discuss compounded alirocumab from a licensed Nevada 503A pharmacy with your prescriber, keeping in mind the manufacturing quality considerations noted above.